Group 1 - The core viewpoint of the news is that MicroPort Robotics has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics and indicating comprehensive coverage of key technologies in minimally invasive diagnosis and treatment [1] - With this approval, the number of surgical robot products approved for market by the company has increased to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach narrow lesions through natural body cavities, which is crucial for the early diagnosis and treatment of early-stage lung cancer [1] Group 2 - As a representative of natural orifice transluminal endoscopic surgery (NOTES) robots, the bronchoscopic surgical robot is seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic breathing conditions, thereby continuously expanding the clinical application boundaries of bronchoscopic interventions [2]